Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06507618 · ClinicalTrials.gov registry record · Phase 3
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
A Phase 3 study of Breast Cancer Female, sponsored by University of Virginia.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 354
- Enrollment target
- 4
- Study locations
NCT06507618 is a Phase 3 study of Breast Cancer Female that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 354 participants, below the 685-participant average among 46 other Breast Cancer Female trials with a reported enrollment target (48% lower). The trial reports 4 study locations across 1 state.
The verdict
NCT06507618, a Phase 3 study of Breast Cancer Female, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 354 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a Phase III, multisite exploratory study for women ≥ 65 years of age with early stage estrogen receptor positive (ER+) breast cancer. These individuals will be treated randomly assigned to one of two groups: Intervention, treated with 3 months of pre-operative endocrine therapy (pre-ET) OR Control, participants follow standard of care and proceed directly to breast cancer surgery. Both arms will be assessed for tolerance and compliance to the endocrine therapy by patient reported outcome (PRO) measures (patient surveys).
Conditions Studied
Interventions
- DRUG Tamoxifen, Letrozole, Anastrozole, or Exemestane
Study Locations (4)
Virginia
- University of Virginia - Charlottesville
- University of Virginia Community Health - Culpeper
- INOVA Schar Cancer - Fairfax
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 354 participants |
| Start Date | 2024-07-19 |
| Est. Completion | 2034-03-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06507618
The ClinicalTrials.gov registry entry for NCT06507618 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 354 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 685-participant average among 46 other Breast Cancer Female trials with a reported enrollment target (48% lower). The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer Female appearing as the primary indexed condition, and to 1 intervention - of which Tamoxifen, Letrozole, Anastrozole, or Exemestane is the first listed.
NCT06507618 reports 4 study locations spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT06507618 about?
NCT06507618 is a clinical study titled "Pre-Operative Window of ET to Inform RT Decisions (POWER II)". This is a Phase III, multisite exploratory study for women ≥ 65 years of age with early stage estrogen receptor positive (ER+) breast cancer. These individuals will be treated randomly assigned to one of two groups: Intervention, treated with 3 months of pre-operative endocrine therapy (pre-ET) OR ...
What is the current status of trial NCT06507618?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 354 participants. The study started on 2024-07-19. Estimated completion is 2034-03-01.
What conditions does trial NCT06507618 study?
This clinical trial studies the following conditions: Breast Cancer Female.
What interventions are being tested in trial NCT06507618?
The interventions under investigation include: Tamoxifen, Letrozole, Anastrozole, or Exemestane (DRUG).
Who is sponsoring clinical trial NCT06507618?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06507618 being conducted?
This trial has 4 study locations across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer Female
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
-
Breast Cancer Resiliency Through Exercise Program (B-REP)
RECRUITING · NA
-
Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.